Related Experiment Video
Updated: Aug 4, 2026
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Anterior chamber infiltration in a patient with Ph+ acute lymphoblastic leukemia in remission with imatinib
Mercedes Hurtado-Sarrió1, Antonio Duch-Samper, Juan Taboada-Esteve
1Ophthalmology Service, La Fe Hospital, Valencia, Spain. hurtado_mer@gva.es
Purpose:
Anterior chamber involvement is unusual in patients with acute lymphoblastic leukemia (ALL) and has never been described in the setting of Ph+ (Philadelphia chromosome-positive) ALL. Moreover, there have been no reports of this complication as a primary relapse in a patient treated with imatinib.
Design:
Interventional case report.
Methods:
A 55-year-old woman with Ph+ ALL in complete remission with imatinib and presenting unilateral anterior uveitis at initial examination was clinically evaluated. Hematologic and ocular studies were performed: blood films, bone marrow smears, and anterior chamber paracentesis with aqueous fluid cytology.
Results:
Although there was no evidence of leukemia in the blood or bone marrow samples, aqueous fluid cytology identified Ph+ positive lymphoblastic leukemic cells.
Conclusions:
The patient had developed anterior chamber infiltration without hematological relapse while treated with imatinib. In our opinion, paracentesis should be performed without delay when uveitis develops in ALL, regardless of systemic relapse.
